0	10	Activation	Activation	NNP
11	13	of	of	IN
14	21	nuclear	nuclear	JJ
22	35	factor-kappaB	factor-kappab	NN
36	39	via	via	IN
40	41	T	t	NN
42	46	cell	cell	NN
47	55	receptor	receptor	NN
56	64	requires	require	VBZ
65	66	a	a	DT
67	70	Raf	Raf	NNP
71	77	kinase	kinase	NNP
78	81	and	and	CC
82	86	Ca2+	ca2+	NN
87	93	influx	influx	NN
93	94	.	.	.

95	105	Functional	functional	JJ
106	113	synergy	synergy	NN
114	121	between	between	IN
122	125	Raf	Raf	NNP
126	129	and	and	CC
130	141	calcineurin	calcineurin	NN
141	142	.	.	.

144	151	Signals	signal	NNS
152	162	transduced	transduce	VBN
163	166	via	via	IN
167	170	the	the	DT
171	174	TCR	TCR	NNP
175	183	activate	activate	VBP
184	187	the	the	DT
188	201	transcription	transcription	NN
202	208	factor	factor	NN
209	216	nuclear	nuclear	JJ
217	230	factor-kappaB	factor-kappaB	NNP
231	232	(	(	(
232	241	NF-kappaB	NF-kappaB	NNP
241	242	)	)	)
242	243	,	,	,
244	249	which	which	WDT
249	250	,	,	,
251	253	in	in	IN
254	258	turn	turn	NN
258	259	,	,	,
260	262	is	be	VBZ
263	271	critical	critical	JJ
272	274	to	to	TO
275	278	the	the	DT
279	294	transcriptional	transcriptional	JJ
295	304	induction	induction	NN
305	307	of	of	IN
308	312	many	many	JJ
313	318	genes	gene	NNS
319	328	important	important	JJ
329	332	for	for	IN
333	336	the	the	DT
337	350	proliferation	proliferation	NN
351	354	and	and	CC
355	365	expression	expression	NN
366	368	of	of	IN
369	370	a	a	DT
371	385	differentiated	differentiate	VBN
386	395	phenotype	phenotype	NN
395	396	.	.	.

397	406	Treatment	Treatment	NNP
407	409	of	of	IN
410	411	T	t	NN
412	417	cells	cell	NNS
418	422	with	with	IN
423	426	the	the	DT
427	434	protein	protein	NN
435	441	kinase	kinase	NNP
442	443	C	C	NNP
444	453	activator	activator	NN
454	457	PMA	PMA	NNP
458	460	in	in	IN
461	472	combination	combination	NN
473	477	with	with	IN
478	482	Ca2+	ca2+	NN
483	493	ionophores	ionophore	NNS
494	500	mimics	mimic	VBZ
501	505	this	this	DT
506	513	process	process	NN
513	514	,	,	,
515	518	and	and	CC
519	522	the	the	DT
523	526	two	two	CD
527	533	agents	agent	NNS
534	537	are	be	VBP
538	543	often	often	RB
544	555	substituted	substitute	VBN
556	559	for	for	IN
560	563	TCR	TCR	NNP
564	575	stimulation	stimulation	NN
575	576	,	,	,
577	586	bypassing	bypass	VBG
587	590	the	the	DT
591	594	TCR	TCR	NNP
594	595	.	.	.

596	600	Here	here	RB
601	603	we	we	PRP
604	612	identify	identify	VBP
613	626	intracellular	intracellular	JJ
627	636	signaling	signaling	NN
637	647	components	component	NNS
648	656	involved	involve	VBN
657	659	in	in	IN
660	670	activation	activation	NN
671	673	of	of	IN
674	683	NF-kappaB	NF-kappaB	NNP
684	693	following	follow	VBG
694	697	TCR	TCR	NNP
698	709	stimulation	stimulation	NN
709	710	.	.	.

711	714	TCR	TCR	NNP
715	724	signaling	signaling	NN
725	728	was	be	VBD
729	738	triggered	trigger	VBN
739	741	by	by	IN
742	750	treating	treat	VBG
751	757	Jurkat	Jurkat	NNP
758	759	T	t	NN
760	765	cells	cell	NNS
766	770	with	with	IN
771	774	PHA	PHA	NNP
775	777	or	or	CC
778	786	anti-CD3	anti-cd3	JJ
787	790	Abs	ab	NNS
790	791	,	,	,
792	795	and	and	CC
796	805	NF-kappaB	NF-kappaB	NNP
806	816	activation	activation	NN
817	820	was	be	VBD
821	830	monitored	monitor	VBN
831	833	by	by	IN
834	849	electrophoretic	electrophoretic	JJ
850	858	mobility	mobility	NN
859	864	shift	shift	NN
865	871	assays	assay	NNS
872	878	and/or	and/or	CC
879	881	by	by	IN
882	898	kappaB-dependent	kappab-dependent	JJ
899	907	reporter	reporter	NN
908	914	assays	assay	NNS
914	915	.	.	.

916	924	Contrary	contrary	JJ
925	927	to	to	TO
928	931	the	the	DT
932	936	idea	idea	NN
937	941	that	that	IN
942	949	protein	protein	NN
950	956	kinase	kinase	NNP
957	958	C	C	NNP
959	961	is	be	VBZ
962	970	involved	involve	VBN
971	973	in	in	IN
974	986	TCR-mediated	tcr-mediated	JJ
987	997	activation	activation	NN
998	1000	of	of	IN
1001	1010	NF-kappaB	NF-kappaB	NNP
1010	1011	,	,	,
1012	1016	high	high	JJ
1017	1022	doses	dose	NNS
1023	1025	of	of	IN
1026	1039	staurosporine	staurosporine	NN
1040	1043	did	do	VBD
1044	1047	not	not	RB
1048	1057	interfere	interfere	VB
1058	1062	with	with	IN
1063	1073	activation	activation	NN
1074	1076	of	of	IN
1077	1086	NF-kappaB	NF-kappaB	NNP
1087	1089	by	by	IN
1090	1093	PHA	PHA	NNP
1093	1094	,	,	,
1095	1100	while	while	IN
1101	1104	the	the	DT
1105	1109	same	same	JJ
1110	1114	dose	dose	NN
1115	1117	of	of	IN
1118	1131	staurosporine	staurosporine	NN
1132	1142	completely	completely	RB
1143	1150	blocked	block	VBD
1151	1161	activation	activation	NN
1162	1164	by	by	IN
1165	1168	PMA	PMA	NNP
1168	1169	.	.	.

1170	1181	PHA-induced	pha-induced	JJ
1182	1198	kappaB-dependent	kappab-dependent	JJ
1199	1207	reporter	reporter	NN
1208	1216	activity	activity	NN
1217	1220	was	be	VBD
1220	1221	,	,	,
1222	1229	however	however	RB
1229	1230	,	,	,
1231	1242	effectively	effectively	RB
1243	1250	blocked	block	VBN
1251	1253	by	by	IN
1254	1255	a	a	DT
1256	1264	dominant	dominant	JJ
1265	1273	negative	negative	JJ
1274	1278	form	form	NN
1279	1281	of	of	IN
1282	1287	Raf-1	raf-1	NN
1287	1288	,	,	,
1289	1299	suggesting	suggest	VBG
1300	1301	a	a	DT
1302	1310	critical	critical	JJ
1311	1315	role	role	NN
1316	1319	for	for	IN
1320	1321	a	a	DT
1322	1325	Raf	Raf	NNP
1326	1332	kinase	kinase	NNP
1332	1333	.	.	.

1334	1337	The	the	DT
1338	1350	TCR-mediated	tcr-mediated	JJ
1351	1361	activation	activation	NN
1362	1364	of	of	IN
1365	1374	NF-kappaB	NF-kappaB	NNP
1375	1378	was	be	VBD
1379	1383	also	also	RB
1384	1393	dependent	dependent	JJ
1394	1396	on	on	IN
1397	1398	a	a	DT
1399	1403	Ca2+	ca2+	NN
1404	1410	influx	influx	NN
1410	1411	,	,	,
1412	1419	because	because	IN
1420	1423	the	the	DT
1424	1428	Ca2+	ca2+	NN
1429	1436	channel	channel	NN
1437	1444	blocker	blocker	NN
1444	1445	,	,	,
1446	1450	SK&F	SK&F	NNP
1451	1456	96365	96365	CD
1456	1457	,	,	,
1458	1460	as	as	RB
1461	1465	well	well	RB
1466	1468	as	as	IN
1469	1474	other	other	JJ
1475	1481	agents	agent	NNS
1482	1486	that	that	WDT
1487	1496	prevented	prevent	VBD
1497	1500	the	the	DT
1501	1505	Ca2+	ca2+	NN
1506	1512	influx	influx	NN
1512	1513	,	,	,
1514	1523	inhibited	inhibit	VBD
1524	1533	NF-kappaB	NF-kappaB	NNP
1534	1544	activation	activation	NN
1544	1545	.	.	.

1546	1560	Cotransfection	cotransfection	NN
1561	1563	of	of	IN
1564	1565	a	a	DT
1566	1580	constitutively	constitutively	RB
1581	1587	active	active	JJ
1588	1592	form	form	NN
1593	1595	of	of	IN
1596	1607	calcineurin	calcineurin	NN
1608	1615	largely	largely	RB
1616	1627	substituted	substitute	VBN
1628	1631	for	for	IN
1632	1635	the	the	DT
1636	1640	Ca2+	ca2+	NN
1641	1652	requirement	requirement	NN
1653	1656	and	and	CC
1657	1665	reversed	reverse	VBD
1666	1669	the	the	DT
1670	1678	blockade	blockade	NN
1679	1681	by	by	IN
1682	1686	SK&F	SK&F	NNP
1687	1692	96365	96365	CD
1692	1693	.	.	.

1694	1704	Consistent	consistent	JJ
1705	1709	with	with	IN
1710	1715	these	these	DT
1716	1728	observations	observation	NNS
1728	1729	,	,	,
1730	1742	coexpression	coexpression	NN
1743	1745	of	of	IN
1746	1760	constitutively	constitutively	RB
1761	1767	active	active	JJ
1768	1773	forms	form	NNS
1774	1776	of	of	IN
1777	1782	Raf-1	raf-1	NN
1783	1786	and	and	CC
1787	1798	calcineurin	calcineurin	NN
1799	1814	synergistically	synergistically	RB
1815	1822	induced	induce	VBD
1823	1839	kappaB-dependent	kappab-dependent	JJ
1840	1848	reporter	reporter	NN
1849	1857	activity	activity	NN
1857	1858	,	,	,
1859	1869	suggesting	suggest	VBG
1870	1871	a	a	DT
1872	1887	physiologically	physiologically	RB
1888	1896	relevant	relevant	JJ
1897	1907	functional	functional	JJ
1908	1919	interaction	interaction	NN
1920	1927	between	between	IN
1928	1931	the	the	DT
1932	1938	kinase	kinase	NNP
1939	1942	and	and	CC
1943	1946	the	the	DT
1947	1958	phosphatase	phosphatase	NN
1958	1959	.	.	.